MA
Mangalam Drugs and Organics Ltd (MANGALAM)
₹27.55
Mkt cap
₹46 Cr
P/E ratio
—
P/B
0.49
Div yield
0.00%
ROE
−34.80%
ROCE
−13.80%
EPS (TTM)
—
Book value
₹56
52W range
23–63
Sector
Healthcare
Price history
Previous close
Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates. [1]
NSE MANGALAMBSE 532637
Health check
Cautious
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−55.92% from high₹28
₹23+20.83% from low₹63
Current
₹27.55
Prev close
₹28.56
Day
−3.54%
Price performance
1D
−3.75%
1W
−5.95%
1M
−7.03%
3M
+2.00%
6M
−9.90%
1Y
−55.87%
YTD
−9.14%
Financials
Revenue, profit & margin
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 81.56 | 97.34 | 102.24 | 76.53 | 79.94 | 88.71 | 72.78 | 57.21 | 49.54 | 58.38 | 67.29 | 57.12 | 79.39 | |
| YoY Sales growth | -24.71% | +53.73% | +12.22% | -12.50% | -1.99% | -8.87% | -28.81% | -25.25% | -38.03% | -34.19% | -7.54% | -0.16% | +60.25% | |
| Expenses | 79.37 | 90.36 | 90.54 | 68.34 | 71.25 | 79.94 | 62.88 | 61.86 | 52.37 | 59.96 | 72.65 | 56.22 | 80.64 | |
| Operating Profit | 2.19 | 6.98 | 11.70 | 8.19 | 8.69 | 8.77 | 9.90 | -4.65 | -2.83 | -1.58 | -5.36 | 0.90 | -1.25 | |
| OPM % | 2.69% | 7.17% | 11.44% | 10.70% | 10.87% | 9.89% | 13.60% | -8.13% | -5.71% | -2.71% | -7.97% | 1.58% | -1.57% | |
| Other Income | 0.03 | 0.00 | 0.05 | 0.02 | 0.14 | 0.13 | 0.47 | 0.14 | 0.03 | 0.22 | 0.09 | 0.11 | 0.17 | |
| Interest | 3.24 | 3.31 | 3.95 | 3.75 | 3.67 | 3.49 | 4.03 | 4.04 | 5.03 | 4.05 | 3.08 | 3.68 | 3.89 | |
| Depreciation | 3.73 | 3.62 | 3.86 | 3.87 | 3.97 | 3.93 | 4.61 | 4.38 | 4.53 | 4.37 | 4.56 | 3.99 | 4.02 | |
| Profit before tax | -4.75 | 0.05 | 3.94 | 0.59 | 1.19 | 1.48 | 1.73 | -12.93 | -12.36 | -9.78 | -12.91 | -6.66 | -8.99 | |
| Tax % | -25.05% | -920.00% | 9.90% | -355.93% | -125.21% | 5.41% | 90.75% | 6.19% | -41.42% | 0.00% | 1.16% | 13.36% | -19.80% | |
| Net Profit | -3.56 | 0.50 | 3.55 | 2.68 | 2.69 | 1.40 | 0.15 | -13.73 | -7.25 | -9.78 | -13.06 | -7.55 | -7.21 | |
| EPS in Rs | -2.25 | 0.32 | 2.24 | 1.69 | 1.70 | 0.88 | 0.09 | -8.67 | -4.58 | -6.18 | -8.25 | -4.77 | -4.56 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202635.65%Promoter
Promoters35.65%
FIIs0.11%
Public64.24%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,880.00 | 36.66 | 4,51,075 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,442.00 | 88.89 | 3,03,749 | 0.26% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,670.00 | 81.82 | 1,77,632 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,424.00 | 97.75 | 1,30,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,189.90 | 26.20 | 1,18,693 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,380.00 | 41.17 | 1,15,267 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,391.80 | 36.21 | 1,12,442 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Mangalam Drugs | ₹29.23 | — | 46 | 0.00% | −7 | +0.55% | 79 | +60.25% | −13.80% |
| Median: 160 Co. | ₹465.83 | 33.99 | 2,012 | 0.08% | 13 | +33.53% | 179 | +20.92% | 14.94% |
Filings
Annual reports15
Concall transcripts3
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Nov - Intimation for Newspaper Publication of unaudited Financial Results (Consolidated and Standalone ) for the quarter ended September 30, 2026 in Financial Express and Marathi Lokstta.Results_Financial Results For September 30, 2026 5 NovBoard Meeting Outcome for Outcome Of Board Meeting For Declaration Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2026. 5 Nov - Board approved Q2 FY2026-27 results; auditors noted NPA classification and going-concern uncertainty.Intimation Under Regulation 36(1) (B) Of SEBI (LODR) Regulations, 2015- Dispatch Of Letter For Non Email Case 4 Nov - 53rd AGM on September 23, 2026; annual report and KYC reminder sent to non-registered email shareholders.Announcement under Regulation 30 (LODR)-Change in Management 2 Nov - Postal ballot approved appointment of Prabhakar Raghunath Zavar as independent director on November 24, 2026.






